RMD ResMed Inc.

Brightree Expands Sleep Therapy Capabilities with ResMed’s AirView Platform

Brightree®, the leading provider of cloud-based software for helping post-acute care companies improve business performance and patient outcomes, today announced that its home medical equipment (HME) billing and business management module has enhanced integration capabilities with AirView™ and myAir™, ResMed’s cloud-based sleep and respiratory care patient management and patient engagement platforms.

The enhanced capabilities include:

  • Creating and updating patients in AirView, minimizing duplicate data entry
  • Receiving automatic patient compliance notifications from AirView, eliminating the need to check multiple systems
  • Inviting patients to register with myAir, helping to engage patients in their own therapy from the start

The latest enhancements integrate within Brightree’s Document Management module. This connection enables HME providers to efficiently perform regular compliance/therapy adherence checks and maintain audit compliance. Specifically, providers can automatically retrieve and store patient compliance reports from AirView directly into Brightree Document Management for provider reference, audit compliance and easy communication to physician referral sources. Compliance report storage frequency can be configured so HME providers can automatically receive a download of an initial compliance report in addition to ongoing 30-, 60- and 90-day reports.

“As the healthcare industry shifts to an outcomes-based model, Brightree and ResMed are working to provide innovative, seamless solutions to create greater visibility into performance and smarter decision making,” said Matt Mellott, Brightree’s president and CEO. “Integrating the AirView patient management platform provides Brightree users added capabilities to optimize business efficiencies and workflows in the HME environment, helping providers focus on improving patient outcomes.”

Initial users of these new capabilities are already seeing the results.

“The Brightree-AirView solution has helped us efficiently organize our workflow, so we can spend more time on our patients’ needs and less time managing operations,” said Crystal Callender, respiratory specialist at BlueDotMedical. “Being able to securely store and retrieve patient compliance information instantly not only enhances our audit compliance and communication process, but also that of our referral sources.”

Brightree and ResMed, a leader in innovative treatments for sleep-disordered breathing, COPD and related respiratory conditions, have a history of collaborating to improve the integration for sleep therapy patients and bring greater workflow efficiency. In 2013, they automated the onboarding of patients that use ResMed S9™ positive airway pressure devices. In 2014, the companies added innovative capabilities that further automated workflows, including support for ResMed’s AirSense™ 10 and AirCurve™ 10 PAP devices, together with patient onboarding, reporting and compliance notifications.

About Brightree

Brightree, a wholly-owned subsidiary of ResMed (NYSE: RMD), is a leading provider of cloud-based software to improve clinical and business performance of post-acute care companies. Ranked one of the top 100 healthcare IT companies in the U.S., Brightree serves more than 2,200 organizations in the HME, home health, hospice, orthotic and prosthetic, HME pharmacy, home infusion, and rehabilitation home care segments. For more information, visit www.brightree.com or call 1.888.598.7797.

Brightree is a registered trademark of Brightree LLC.

EN
22/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

ResMed Inc: 2 directors

A director at ResMed Inc sold 2,000 shares at 248.830USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 20...

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:•Date:Thursday, January 29, 2026•Time:1:30 p.m. PST /...

 PRESS RELEASE

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthca...

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay...

 PRESS RELEASE

Resmed Receives FDA Clearance for Personalized Therapy Comfort Setting...

Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy Technology uses real-world sleep data and machine learning to help people with sleep apnea start and stay on therapy  SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Setting...

 PRESS RELEASE

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 202...

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026 Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0%Income from operations increased 15%; non-GAAP income from operations up 19%Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55Operating cash flow of $457 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) to...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch